BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25029935)

  • 1. Preclinical studies of SPECT and PET tracers for NET.
    Brom M; Boerman O; Gotthardt M; Oyen WJ
    PET Clin; 2014 Jan; 9(1):63-9. PubMed ID: 25029935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors.
    Pepe G; Bombardieri E; Lorenzoni A; Chiti A
    PET Clin; 2014 Jan; 9(1):11-26. PubMed ID: 25029930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled glucagon-like peptide-1 analogues: a new pancreatic β-cell imaging agent.
    Zhang Y; Chen W
    Nucl Med Commun; 2012 Mar; 33(3):223-7. PubMed ID: 22262216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State of the Art and Recent Developments of Radiopharmaceuticals for Pancreatic Neuroendocrine Tumors Imaging.
    Carollo A; Papi S; Grana CM; Mansi L; Chinol M
    Curr Radiopharm; 2019; 12(2):107-125. PubMed ID: 30843499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals.
    Wu H; Liang S; Liu S; Pan Y; Cheng D; Zhang Y
    Nucl Med Commun; 2013 Jul; 34(7):701-8. PubMed ID: 23652208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours.
    Cuccurullo V; Di Stasio GD; Mansi L
    Curr Radiopharm; 2019; 12(2):98-106. PubMed ID: 30727940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Radionuclide imaging of neurendocrine tumors: biological basis and diagnostic results].
    Genovese EA; Mallardo V; Rossi M; Vaccaro A; Raucci A; Della Vecchi N; Romano G; Califano T; Schillirò F
    Recenti Prog Med; 2013; 104(7-8):340-4. PubMed ID: 24042404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Other PET tracers for neuroendocrine tumors.
    Koopmans KP; Glaudemans AW
    PET Clin; 2014 Jan; 9(1):57-62. PubMed ID: 25029934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents.
    Smith DL; Breeman WA; Sims-Mourtada J
    Appl Radiat Isot; 2013 Jun; 76():14-23. PubMed ID: 23232184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
    Ito T; Jensen RT
    Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):15-24. PubMed ID: 27875420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of neuroendocrine tumors.
    Rufini V; Calcagni ML; Baum RP
    Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Imaging and radioguided surgery of tumors NETs].
    Schillirò F; Mallardo V; Manna A; Fontanarosa A; Califano T; Della Vecchia N; Romano G; Di Crescenzo V; Genovese EA
    Recenti Prog Med; 2013; 104(7-8):336-9. PubMed ID: 24042403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear medicine procedures in the diagnosis of NET: a historical perspective.
    Maffione AM; Karunanithi S; Kumar R; Rubello D; Alavi A
    PET Clin; 2014 Jan; 9(1):1-9. PubMed ID: 25029929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of
    Kimura H; Matsuda H; Ogawa Y; Fujimoto H; Toyoda K; Fujita N; Arimitsu K; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H
    Bioorg Med Chem; 2017 Feb; 25(4):1406-1412. PubMed ID: 28089587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide imaging with somatostatin analogues: more than cancer probes.
    Cascini GL; Cuccurullo V; Tamburrini O; Rotondo A; Mansi L
    Curr Radiopharm; 2013 Mar; 6(1):36-40. PubMed ID: 23470033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
    Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
    J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
    Panagiotidis E; Bomanji J
    PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a Fluorescent and Radiolabeled Hybrid Somatostatin Analog In Vitro and in Mice Bearing H69 Neuroendocrine Xenografts.
    Santini C; Kuil J; Bunschoten A; Pool S; de Blois E; Ridwan Y; Essers J; Bernsen MR; van Leeuwen FW; de Jong M
    J Nucl Med; 2016 Aug; 57(8):1289-95. PubMed ID: 27127222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.